Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Breast Neoplasms 67 Prostatic Neoplasms 49 Multiple Myeloma 29 Neoplasm Metastasis 27 Osteoporosis 16 Pain 15 Carcinoma, Non-Small-Cell Lung 10 Neoplasms 9 Lung Neoplasms 8 Osteosarcoma 7 Neoplasms, Plasma Cell 7 Neuroblastoma 6 Carcinoma, Renal Cell 6 Bone Diseases, Metabolic 6 Humoral Hypercalcemia Of Malignancy 5 Bone Neoplasms 5 Fractures, Bone 4 Bone Diseases 4 Sarcoma, Ewing 3 Sarcoma 3 Lymphoma 3 Kidney Neoplasms 3 Uterine Cervical Neoplasms 2 Triple Negative Breast Neoplasms 2 Spinal Cord Compression 2 Small Cell Lung Carcinoma 2 Rhabdomyosarcoma 2 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Pleural Effusion, Malignant 2 Ovarian Neoplasms 2

Interventions

Cyclophosphamide 22 blinatumomab 18 Cytarabine 15 fludarabine 13 Azacitidine 12 venetoclax 10 fludarabine phosphate 10 Rituximab 8 Lenalidomide 7 Dexamethasone 7 Methotrexate 6 Daunorubicin 6 Mercaptopurine 5 daratumumab 4 Whole-Body Irradiation 4 Vincristine 4 Melphalan 4 Idarubicin 4 Etoposide 4 Busulfan 4 pembrolizumab 3 obinutuzumab 3 Radiotherapy 3 Maintenance 3 Immunotherapy, Adoptive 3 Imatinib Mesylate 3 Granulocyte Colony-Stimulating Factor 3 Drug Therapy 3 Cladribine 3 Asparaginase 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Neoplasm, Residual × Zoledronic Acid × Clear all

NCT00172068 2009-12-23

MRD-1

Novartis

Phase 2 Terminated

Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon ⚡